Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG (NOVN)

190
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Swiss Exchange
12/15/2014 12/16/2014 12/17/2014 12/18/2014 12/19/2014 Date
88.65(c) 89.1(c) 88.95(c) 92.1(c) 93.05(c) Last
6 109 579 9 125 344 8 091 877 7 905 067 17 054 248 Volume
-2.37% +0.51% -0.17% +3.54% +1.03% Change
More quotes
Company
Novartis AG develops, manufactures, and markets healthcare products.It operates through the following segments: Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, and Consumer Health.The Pharmaceuticals segment provides patent-protected prescription medicines.The Alcon segment offers... 
Sector
Pharmaceuticals
Calendar
01/12Presentation
More about the company
Surperformance© ratings of Novartis AG
Trading Rating : Investor Rating :
More Ratings
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 58 424 M
EBIT 2014 14 598 M
Net income 2014 10 703 M
Debt 2014 4 308 M
Yield 2014 2,84%
Sales 2015 56 952 M
EBIT 2015 15 288 M
Net income 2015 11 255 M
Debt 2015 6 963 M
Yield 2015 2,97%
PER 2014 22,04
PER 2015 20,42
EV / Sales 2014 4,47x
EV / Sales 2015 4,63x
Capitalization 257 003 M
More Financials
Latest news on NOVARTIS AG
2d ago VERNALIS : Says Novartis Stops Development Work On AUY922
3d ago GSK shareholders approve asset swap deal with Novartis
3d ago NOVARTIS : ++ Suspicious post-flu vaccine death reported in Parma ++
3d ago NOVARTIS : CMS to Sell Terbinafine Hydrochloride Tablets, Parlodel Tab
3d ago NOVARTIS : Patent Application Titled "RNAi Inhibition of Serum Amyloid a for Tre..
3d ago NOVARTIS : Patent Application Titled "Method for Determining the Surface Concent..
3d ago NOVARTIS : Secures FDA Approval for Signifor LAR
4d ago NOVARTIS : Patent Application Titled "Use of IL-1 Beta Binding Antibodies" Publi..
More news
Sector news
2h ago MERCK : buys new-cancer-drug firm
10h ago Fear factor fades as global M&A hits seven-year high
1d ago AstraZeneca CEO says new Pfizer bid unlikely - Swedish daily DI
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF